Investigational Drug for Aspirin Exacerbated Respiratory Disease (AERD)

Trial ID:
IRB-17-7001
Andrew A. White, M.D.
This study will compare the investigational drug ifetroban to a placebo for improving symptoms and quality of life in patients with AERD. Participants will receive study drug or placebo once daily for up to 8 weeks, and will have a telephone visit at week 1 with additional clinic follow-up visits at 4, 8, and 10 weeks.

Inclusion Criteria

  • Have a history of physician-diagnosed asthma
  • Have a history of at least two reactions to oral aspirin
  • Be at least 18 years of age or older
  • Active AERD symptoms within two weeks of starting treatment

Exclusion Criteria

  • Be a current smoker or have used tobacco within the last three months
  • Have participated in a clinical trial with ifetroban within the past three months.

Additional Info

  • Participants will also be asked to donate nasal fluid, blood and urine specimens to be stored and used for future research on AERD.

Contact Info:

  • heather catchpole
  • Catchpole.heather@scrippshealth.org